

EXHIBIT 1



UNITED STATES DEPARTMENT OF COMMERCE
 Patent and Trademark Office
 Address: COMMISSIONER OF PATENTS AND TRADEMARKS
 Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
06,075,429	11/30/01	LIH	100

TERESA M. MARSHALL & DICKINELL
 TWO FIRST NATL. PLAZA, STE. 2100
 20 SOUTH CLARK ST.
 CHICAGO, IL 60606

EXAMINER	
MILSOMING	
ART UNIT	PAPER NUMBER
100	100
DATE MAILED: 11.03.02	

This is a communication from the examiner in charge of your application.
 COMMISSIONER OF PATENTS AND TRADEMARKS

This application has been examined Responsive to communication filed on _____ This action is made final.

A shortened statutory period for response to this action is set to expire 3 month(s), _____ days from the date of this letter.
 Failure to respond within the period for response will cause the application to become abandoned. 35 U.S.C. 133

Part I THE FOLLOWING ATTACHMENT(S) ARE PART OF THIS ACTION:

- | | |
|---|---|
| 1. <input checked="" type="checkbox"/> Notice of References Cited by Examiner, PTO-892. | 2. <input type="checkbox"/> Notice re Patent Drawing, PTO-948. |
| 3. <input checked="" type="checkbox"/> Notice of Art Cited by Applicant, PTO-1449 | 4. <input type="checkbox"/> Notice of Informal Patent Application, Form PTO-152 |
| 5. <input type="checkbox"/> Information on How to Effect Drawing Changes, PTO-1474 | 6. <input type="checkbox"/> _____ |

Part II SUMMARY OF ACTION

1. Claims 1-72 are pending in the application.
 Of the above, claims 1-13, 16, 37-37 and 59-60 are withdrawn from consideration.
2. Claims _____ have been cancelled.
3. Claims _____ are allowed.
4. Claims 14, 15, 17-36, 58 and 61-72 are rejected.
5. Claims _____ are objected to.
6. Claims 1-72 are subject to restriction or election requirement.
7. This application has been filed with informal drawings which are acceptable for examination purposes until such time as allowable subject matter is indicated.
8. Allowable subject matter having been indicated, formal drawings are required in response to this Office action.
9. The objected or substitute drawings have been received on _____ . These drawings are acceptable; not acceptable (see explanation).
10. The proposed drawing correction and/or the proposed additional or substitute sheet(s) of drawings, filed on _____ has (have) been approved by the examiner. disapproved by the examiner (see explanation).
11. The proposed drawing correction, filed _____, has been approved. disapproved (see explanation). However, the Patent and Trademark Office no longer makes drawing changes. It is now applicant's responsibility to ensure that the drawings are corrected. Corrections MUST be effected in accordance with the instructions set forth on the attached letter "INFORMATION ON HOW TO EFFECT DRAWING CHANGES", PTO-1474.
12. Acknowledgment is made of the claim for priority under 35 U.S.C. 119. The certified copy has been received not been received
 been filed in parent application, serial no. _____; filed on _____
13. Since this application appears to be in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11; 453 D.G. 213. 205
14. Other

PTOL-324 (Rev. 7-82)

EXAMINER'S ACTION 198

A 47862

Serial No. 675298
Art Unit 127

-2-

Restriction to one of the following inventions is required under 35 U.S.C. 121:

I. Claims 1-13, 16, 39-41, 47-54 and 59, drawn to polypeptide, classified in Class 260, subclass 112.

II. Claims 14, 15, 17-36, 58 and 61-72, drawn to DNA, classified in Class 536, subclass 27.

III. Claims 37-38, drawn to plasmid, classified in Class 435, subclass 317.

IV. Claims 42-46, drawn to cells, classified in Class 435, subclass 240.

V. Claims 55-57, drawn to pharmaceutical composition, classified in Class 435, subclass 177.

VI. Claim 60, drawn to assay, classified in Class 435, subclass 6.

Inventions I and II are related as process of making and product made.

The inventions are distinct if either (1) the process as claimed can be used to make another and materially different product, or (2) the product as claimed can be made by another and materially different process. MPEP 806.05(f).

In this case, the product as claimed may be made by a materially different product, such as isolation from a naturally occurring source.

Inventions II and III are related as product and process of use.

The inventions are distinct if either (1) the process for using the product as claimed can be practiced with another and materially different product, or (2) the product as claimed can be used in a materially different process of using the product. MPEP 806.05(h).

A 47863

206

1.89 199

Serial No. 675298
Art Unit 127

-3-

In this case, the product as claimed may be made by a materially different product, such as isolation from urine.

Inventions I and V are related as subcombinations disclosed as useable together in a single combination. The subcombinations are distinct from each other if they are shown to be separately useable. In the instant case, invention I has separate utility such as use in an assay. See MPEP 806.05(d).

Inventions I and VI are related as subcombinations disclosed as useable together in a single combination. The subcombinations are distinct from each other if they are shown to be separately useable. In the instant case, invention I has separate utility such as use as a pharmaceutical. See MPEP 806.05(d).

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter restriction for examination purposes as indicated is proper.

In a preliminary amendment, filed April 24, 1986, Applicant elected group II, claims 14, 15, 17-36, 58 and 61-72 without traverse. The non-elected claims are withdrawn from further consideration.

Chingwin et al (Ref. C8) has not been considered because a complete copy of the article was not among the papers in applicants prior art statement.

A 47864

207

Serial No. 675298

-4-

Art Unit 127

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

The specification is objected to under 35 U.S.C. 112, first paragraph, as failing to provide an enabling disclosure. The invention depends on certain specific plasmids/microorganisms. As such, a deposit is required under 35 USC 112. Conditions surrounding the deposit which must be met are enumerated in MPEP 608.01(p)(C). The deposit papers supplied with the preliminary amendment have been considered. However, it is not clear that applicants promises to replace these cultures should this become necessary. Assurance of compliance may be in the form of an oath or declaration.

Claims 14, 15, 17-36, 58 and 61-72 are rejected under 35 U.S.C. 112, first paragraph, for the reasons set forth in the above objection to the specification.

Claims 14, 15, 17-36, 58 and 61-72 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. Claims 14, 15, 62, 64, 66,

A 47865

208

Serial No. 675298
Art Unit 127

-5-

68, and claims depending from them are unduly alter-
native in their recitation of "procaryotic or
eucaryotic" host cell as these are not equivalent terms.
Claims 14, 17, 34, 58, 69-72 and claims depending from
them are indefinite in that the fragment size claimed is
so vague as to read on single base pairs. Purported
limitations as to "biological properties" without
further characterizations are so indefinite as to be
meaningless. Claims 14, 20, 23, 27, 30, 58 and those
depending on them are indefinite in that they refer to a
figure when they can be adequately expressed in words.
Claim 14 has improper Markush language. Claim 69 omits
the number of the claim it is dependent upon.

35 U.S.C. 101 reads as follows:

Whoever invents or discovers any new and useful
process, machine, manufacture, or composition of
matter or any new and useful improvement thereof,
may obtain a patent therefor, subject to the con-
ditions and requirements of this title.

Claims 14, 15, 17-36, 58 and 61-72 provisionally
rejected under 35 U.S.C. 101 as claiming the same inven-
tion as that of claims 13-24 and 27 of copending appli-
cation Serial No. 582185.

This is a provisional double patenting rejection
since the conflicting claims have not in fact been
patented.

Claims 14, 15, 17-36, 58 and 61-72 are provi-
sionally rejected under 35 U.S.C. 101 as claiming the
same invention as that of claims 1-48 of copending
application Serial No. 655841.

A 47866

Serial No. 675298
Art Unit 127

-6-

This is a provisional double patenting rejection since the conflicting claims have not in fact been patented.

Claims 14, 24, 34 and 36 are rejected under 35 U.S.C. 101 because the claimed invention is directed towards non-statutory subject matter. claims 14, 24, 34 and 36 all read on the naturally occurring erythropoietin gene and portions of it present in erythropoietin-producing cells. The purported limitation of "manufactured" in claim 24 does not distinguish over naturally occurring as it could read on DNA manufactured by the cell naturally. As products of nature, these DNA sequences are not subject to patent protection.

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless-

(a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for patent.

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 14, 24, 34 and 36 are rejected under 35 U.S.C. 102 (b) as anticipated by or, in the alternative, under 35 U.S.C. 103 as obvious over Sugimoto et al. Sugimoto et al teach a cell line which produces erythropoietin. It appears that the DNA inherently present in

A 47867

210

... 203

Serial No. 675298
Art Unit 127

-7-

these cells is the same as the DNA claimed. Thus applicants DNA is the same as or obvious over that of Sugimoto et al.

Claims 14, 15, 17, 18, 20, 24, 25, 26, 27, 33, 34, 58, 61, 62, 63, 64, 65, 66, 69, 70, and 71 are rejected under 35 U.S.C. 102(a) as being anticipated by Lee-Huang et al. The DNA sequences specifically claimed appear to be the same as those made by Lee-Huang et al.

Claims 14, 15, 17-20, 24, 33, 34, 36, 58, 61, 62, 63, 64, 65, 66, 69, 70, 71 are rejected under 35 U.S.C. 102 (a) as anticipated by or, in the alternative, under 35 U.S.C. 103 as obvious over anticipated Lin et al.

The sequences cloned by Lin et al appear to be the same as those of the instant case.

The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action:

A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Subject matter developed by another person, which qualifies as prior art only under subsection (f) and (g) of section 102 of this title, shall not preclude patentability under this section where the subject matter and the claimed invention were, at the time the invention was made, owned by the same person or subject to an obligation of assignment to the same person.

A 47868

211

Lee et al

Serial No. 675298
Art Unit 127

-8-

Claims 14, 15, 17, 18, 20, 21, 22, 23, 24, 34, 35, 36, 58 and 61-72 rejected under 35 U.S.C. 103 as being unpatentable over Sugimoto et al in view of Sugimoto et al in view of Paddock and Cohen et al. Sugimoto et al teach cells from which erythropoietin RNA can be isolated, as they have a high erythropoietin production. Paddock teaches making cDNA from RNA, and Cohen et al teach cloning of a desired strand of DNA. Further, Sugimoto et al suggest that the erythropoietin gene could be so cloned. Thus it would be obvious to one of ordinary skill in the art to isolate and clone the erythropoietin gene, as the techniques for doing so are well known in the art and the expected result is obtained.

Claim 19 is rejected under 35 U.S.C. 103 as being unpatentable over Sugimoto et al in view of Paddock and Cohen et al as applied to claims 14, 15, 17, 18, 20, 21, 22, 23, 24, 34, 35, 36, 58 and 61-72 above, and further in view of Farber et al. The process and production of human EPO DNA is obvious as explained supra. Farber et al teach a monkey source of RNA for erythropoietin, and its subsequent translation. Thus in the absence of unexpected results, it would be obvious to substitute one source of the mRNA for another known source.

Claims 25-30 are rejected under 35 U.S.C. 103 as being unpatentable over Sugimoto et al in view of Paddock and Cohen et al as applied to claims 14, 15, 17,

A 47869

212

102

Serial No. 675298
Art Unit 127

-9-

18, 20, 21, 22, 23, 24, 25, 34, 35, 36 58 and 61-72 above, and further in view of Bennetsen et al or Gouy et al. The process and production of the DNA is obvious, as discussed supra. Using codons which are known to be preferred by Lewin. The process and production of the DNA is obvious, as discused supra. Lewin teaches radioactively labeled DNA, and its use. Thus in the absence of unexpected results, it would be obvious to be label applicants' DNA, as its use is the same.

Any inquiry concerning this communication should be directed to Joanne M. Giesser at telephone number 703-557-0296.

Giesser:st. *JMG*
6-16-86

Thomas G. Wiseman
THOMAS G. WISEMAN
SUPERVISORY PATENT EXAMINER
ART UNIT 127

A 47870

213

FORM PTO 892 (REV. 3-78)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		SERIAL NO. 175298	GROUP/UNIT 127	ATTACHMENT TO PAPER NUMBER 8		
NOTICE OF REFERENCES CITED				APPLICANT(S) Lin				
U.S. PATENT DOCUMENTS								
	DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE		
*	A 4377513	3/22/83	Sugimoto et al	260	112	8/10/81		
*	B 4503151	3/5/85	Paddock	435	68	11/22/82		
*	C 4468464	8/28/84	Cohen et al	435	317	11/9/78		
	D							
	E							
	F							
	G							
	H							
	I							
	J							
	K							
FOREIGN PATENT DOCUMENTS								
	DOCUMENT NO.	DATE	COUNTRY	NAME	CLASS	SUB-CLASS	PERTINENT SHTS. DWG	PP. SPEC.
	L							
	M							
	N							
	O							
	P							
	Q							
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)								
*	R	Lee-Huang, 1984 "Cloning and expression of human erythropoietin cDNA in <i>E. coli</i> " <u>PNAS</u> v 81 p 2705-12						
	S	Lin et al, 1984 "Cloning of the monkey erythropoietin gene" (Abstract) <u>J Cell Biochem</u> Suppl 8 B p 45						
*	T	Farber et al, 1983 "Translation of mRNA from anemic baboon kidney into biologically active erythropoietin" <u>Exp. Hematol</u> v 11 Suppl 4 Abstr 101						
	U	Gouy et al, 1982 "Codon usage in bacteria; correlation with gene expressivity" <u>Nucleic Acids Res.</u> v 10 7055-7074						
EXAMINER Jeanne M. Sisco		DATE 6/2/86		A 47871				
* A copy of this reference is not being furnished with this office action. (See Manual of Patent Examining Procedure, section 707.05 (a).)								

Lin 2/11

214

Sheet 1 of 18

Form PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	APPT. DOCKET NO. 7183	SERIAL NO. 675,298
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		
APPLICANT FU-KUEN LIN		FILING DATE NOV. 30, 1984
		GROUP 127

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
JMY	A1 3 0 3 3 7 5 3	5/8/52	White, et al.				
JMY	A2 3 8 6 5 8 0 1	2/11/75	Chiba, et al.				
JMY	A3 4 2 3 7 2 2 4	12/2/80	Cohen et al.				
JMY	A4 4 2 6 4 7 3 1	4/28/81	Shine				
JMY	A5 4 2 7 3 8 7 5	6/16/81	Manis				
JMY	A6 4 2 9 3 6 5 2	10/6/81	Cohen				
JMY	A7 4 3 5 8 5 3 5	11/9/82	Falkow, et al.				
JMY	A8 4 3 7 7 5 1 3	3/22/83	Suginoto, et al.				
JMY	A9 4 3 9 4 4 4 3	7/13/83	Weissman, et al.				
JMY	A10 4 3 9 7 8 4 0	8/9/83	Takezawa, et al.				
JMY	A11 4 3 9 9 2 1 6	8/16/83	Axel, et al.				

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO	
JMY	B1 0 0 7 0 6 8 5	1/26/83	European Patent Office				
JMY	B2 0 0 7 0 6 8 7	1/26/83	European Patent Office				
JMY	B3 0 0 7 7 6 7 0	4/27/83	European Patent Office				
JMY	B4 0 0 9 3 6 1 9	11/9/83	European Patent Office				
JMY	B5 0 1 1 6 4 4 6	8/22/84	European Patent Office				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
JMY	C1 Adamson, Hosp.Practice, 18(12), 49-57 (1983)
JMY	C2 Anderson, et al., P.N.A.S. (USA), 80, pp. 6838-6842 (1983)
JMY	C3 Baciu, et al., Ann.N.Y.Acad.Sci., 414, pp. 66-72 (1983)

EXAMINER <i>Jeanne M. Giesse</i>	DATE CONSIDERED <i>June 2, 1986</i>
-------------------------------------	--

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

A 47872

184 208

215

Sheet 2 of 12

Form PTO-1449 REV. 5-83		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE			ATTY. DOCKET NO. 7183	SERIAL NO. 675,298
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>					APPLICANT FU-KUEN LIN	
					FILING DATE Nov. 30, 1984	GROUP 127
U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
JMY	A12 4 4 6 5 6 2 4	8/14/84	Chiba, et al.	—	—	
JMY	A13 4 6 3 7 2 4		Forie (not enclosed)	See, 85		
JMY	A14 4 8 3 4 5 1	4/15/83	Alton, et al. (not enclosed)	See, 811		
JMY	A15 4 8 7 7 5 3		Bitter (not enclosed)	See, 89		
JMY	A16 6 3 6 7 2 7		Morris (not enclosed)	See, 812		
JMY	A17 4 4 6 8 4 6 8	8/28/84	Cohen et al.	—	—	
JMY	A18 4 5 0 2 8 5 1	5/5/85	Paddock	—	—	
JMY	A19 4 4 4 2 2 0 5	4/10/84	Hamer et al.	—	—	
JMY	A20 4 4 1 1 9 9 4	10/25/83	Gilbert et al.	—	—	
JMY	A21 4 3 3 8 3 9 7	7/6/82	Gilbert et al.	—	—	
JMY	A22 4 5 6 8 4 8 8	2/4/86	Lee-Huang	—	—	
FOREIGN PATENT DOCUMENTS						
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
EP: JMY	B6 0 1 1 7 0 5 8	8/29/84	European Patent Office	—	—	
JMY	B7 0 1 1 7 0 5 9	8/29/84	European Patent Office	—	—	
JMY	B8 0 1 1 7 0 6 0	8/2/84	European Patent Office	—	—	
JMY	B9 0 1 2 3 2 9 4	4/19/84	European Patent Office	—	—	
JMY	B10 2 0 8 5 8 8 7	5/6/82	United Kingdom	—	—	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)						
JMY	C4	Baron, et al., Cell, 28, pp. 395-404 (1982)				
JMY	C5	Beaucage, et al., Tetrahedron Letters, 22, pp. 1859-1862 (1981)				
JMY	C6	Billat, et al., Expt. Hematol., 10(1) 133-140 (1982)				
EXAMINER Joanne M. Siscoe				DATE CONSIDERED June 2, 1986		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.						

A 47873

209.187

216

Sheet 4 of 12

FORM PTO-1449

Atty. Docket No.
7183

Serial No.
675,298

Applicant: FU-KUEN LIN

Filing Date: November 30, 1984

Group Art Unit 127

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

OTHER DOCUMENTS (cont'd.)

(Including Author, Title, Date, Pertinent pages, etc.)

<i>JMY</i>	C10	Choo, et al.	<u>Nature</u> , 299, pp. 178-180 (1982) <i>14</i>
<i>JMY</i>	C11	Choppin, et al.	<u>Blood</u> , 64(2) 341-347 (1984) <i>14</i>
<i>JMY</i>	C12	Chou, et al.	<u>Biochem.</u> , 13, 222-245 (1974) <i>14</i>
<i>JMY</i>	C13	Chou, et al.	<u>Advances in Enzymology</u> , 47, 45-47 (1978) <i>14</i>
<i>JMY</i>	C14	Chou, et al.	<u>Ann.Rev.Biochem.</u> , 47, 251-77 (1978) <i>14</i>
<i>JMY</i>	C15	Claus-Walker, et al.	<u>Arch.Phys.Med.Rehabil.</u> , 65, 370-374 (1984) <i>14</i>
<i>JMY</i>	C16	Congote	<u>Biochem.Biophys.Res.Comm.</u> , 115(2), 477-483 (1983) <i>14</i>
<i>JMY</i>	C17	Congote	<u>Anal.Biochem.</u> , 140, 428-433 (1984) <i>14</i>
<i>JMY</i>	C18	Congote, et al.	Abstract 364, Proceedings 7th International Congress of Endocrinology (Quebec City, Quebec, July 1-7, 1984) <i>14</i>
<i>JMY</i>	C19	Cotes, et al.	<u>Nature</u> , 191, 1065-1067 (1961) <i>14</i>
<i>JMY</i>	C20	Cotes, et al.	<u>Brit.J.Obstet.Gyneacol.</u> , 90(4), 304-311 (1983) <i>14</i>
<i>JMY</i>	C21	Dainiak, et al.	<u>Cancer</u> , 51(6), 1101-1106 (1983) <i>14</i>
<i>JMY</i>	C22	Das, et al.	<u>P.N.A.S. (USA)</u> , 80, pp. 1531-1535 (1983) <i>14</i>
<i>JMY</i>	C23	Davis, et al.	"A Manual for Genetic Engineering, Advanced Bacterial Genetics", Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y. (1980), pp. 55-58 & 174-176 <i>14</i> <i>14</i>

A 47875

considered 6/2/86 Joanne M. Gessner
189 211

218

Sheet 5 of 12

FORM PTO-1449

Atty. Docket No.
7183Serial No.
675,298

Applicant: FU-KUEN LIN

Filing Date: November 30, 1984

Group Art Unit 127

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

OTHER DOCUMENTS (cont'd.)

(Including Author, Title, Date, Pertinent pages, etc.)

<i>JMY</i> C24	Dessypris, et al.	<u>Brit.J.Haematol.</u> , <u>56</u> , 295-306 (1984) ₁₄
<i>JMY</i> C25	Dreesman, et al.	<u>Nature</u> , <u>295</u> , 158-160 (1982) ₁₄
<i>JMY</i> C26	Dunn	"Current Concepts in Erythro- poiesis", John Wiley & Sons, Chichester, England, 1983
<i>JMY</i> C27	Dunn, et al.	<u>Expt.Hematol.</u> , <u>11(7)</u> , 590-600 (1983) ₁₄
<i>JMY</i> C28	Dunn, et al.	<u>Eur.J.Appln.Physiol.</u> , <u>52</u> , 178-182 (1984) ₁₄
<i>JMY</i> C29	Emmanouel, et al.	<u>Am.J.Physiol.</u> , <u>247</u> (1 Pt 2), F168-76 (1984)
<i>JMY</i> C30	Eschbach, et al.	<u>J.Clin.Invest.</u> , <u>74(2)</u> , pp. 434- 441 (1984) ₁₄
<i>JMY</i> C31	Farber	<u>Clin.Res.</u> , <u>31(4)</u> 769A (1983)
<i>JMY</i> C32	Farber, et al.	<u>Exp.Hematol.</u> , <u>11.</u> , Supp. 14, Abstract 101 (1983)
<i>JMY</i> C33	Farber, et al.	<u>Blood</u> , <u>62</u> , No. 5, Supp. No. 1, Abstract 392, 122a (1983)
<i>JMY</i> C34	Fiddes, et al.	<u>J.Mol. & App.Genetics</u> , <u>1</u> , pp. 3- 18 (1981) ₁₄
<i>JMY</i> C35	Finch	<u>Blood</u> , <u>60(6)</u> , 1241-1246 (1982) ₁₄
<i>JMY</i> C36	Fisher, et al.	<u>Steroids</u> , <u>30(6)</u> , 833-845 (1977)
<i>JMY</i> C37	Gasser, et al.	<u>P.N.A.S. (USA)</u> , <u>79</u> , 6522-6526 (1982) ₁₄
<i>JMY</i> C38	Gene Screen	New England Nuclear, Catalog No. NEF-972
<i>JMY</i> C39	Gibson, et al.	<u>Pathology</u> , <u>16</u> , 155-156 (1984) ₁₄

A 47876

Considered June 2, 1986
Jeanne M. Guesser

190212

219

Sheet 6 of 12

DRM PTO-1449

Atty. Docket No.
7183

Serial No.
675,298

Applicant: FU-KUEN LIN

Filing Date: November 30, 1984

Group Art Unit 127

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

OTHER DOCUMENTS (cont'd.)
(Including Author, Title, Date, Pertinent pages, etc.)

<i>Jmy</i> C40	Goldwasser,	<u>J.Cell.Physiol.</u> , <u>110(Supp. 1)</u> , <u>133-135</u> (1982) ₁₄
<i>Jmy</i> C41	Goldwasser, et al.	<u>Endocrinology</u> , <u>97</u> , 2, 315-323 (1975) ₁₄
<i>Jmy</i> C42	Gray, et al.	<u>Nature</u> , <u>295</u> , 503-508 (1982) ₁₄
<i>Jmy</i> C43	Gray, et al.	<u>Biotechnology</u> , <u>2</u> , 161-165 (1984) ₁₄
<i>Jmy</i> C44	Green, et al.	<u>Cell</u> , <u>28</u> , 477-487 (1982) ₁₄
<i>Jmy</i> C45	Haddy	<u>Am.Jour.Ped.Hematol./Oncol.</u> , <u>4</u> , <u>191-196</u> (1982) ₁₄
<i>Jmy</i> C46	Haga, et al.	<u>Acta.Pediatr.Scand.</u> , <u>72</u> , 827-831, (1983) ₁₄
<i>Jmy</i> C47	Hagiwara, et al.	<u>Blood</u> , <u>63(4)</u> , 828-835 (1984) ₁₄
<i>Jmy</i> C48	Hammond, et al.	<u>Ann.N.Y.Acad.Sci.</u> , <u>149</u> , 516-527 (1968) ₁₄
<i>Jmy</i> C49	Hellmann, et al.	<u>Clin.Lab.Haemat.</u> , <u>5</u> , 335-342 (1983) ₁₄
<i>Jmy</i> C50	Hewick, et al.	<u>J.Biol.Chem.</u> , <u>256</u> , 7990-7997 (1981) ₁₄
<i>Jmy</i> C51	Hopp, et al. (1981)	<u>P.N.A.S. (USA)</u> , <u>78</u> , 3824-3828 <u>D-7182</u> ₁₄
<i>Jmy</i> C52	Jaye, et al.	<u>Nuc.Acids Res.</u> , <u>11</u> , pp. 2325-2335 (1983) ₁₄
<i>Jmy</i> C53	Jelkman, et al.	<u>Expt.Hematol.</u> , <u>11(7)</u> , 581-588 (1983) ₁₄
<i>Jmy</i> C54	Kaiser, et al.	<u>Science</u> , <u>223</u> , pp. 249-255 (1984) ₁₄
<i>Jmy</i> C55	Kalmanti	<u>Kidney Int.</u> , <u>22</u> , 383-391 (1982) ₁₄
<i>Jmy</i> C56	Karn, et al.	<u>P.N.A.S. (USA)</u> , <u>77</u> , pp. 5172-5176 (1980) ₁₄

A 47877

*Considered June 2, 1986
Janne M. Geeser*

191 213

220

Sheet 7 of 12

ORM PTO-1449

Atty. Docket No.
7183

Serial No.
675,298

Applicant: FU-KUEN LIN

Filing Date: November 30, 1984

Group Art Unit 127

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

OTHER DOCUMENTS (cont'd.)
(Including Author, Title, Date, Pertinent pages, etc.)

<i>JMY</i>	C57	Katsuoka, et al.	<u>Gann</u> , 74, 534-541 (1983)
<i>JMY</i>	C58	Kornblitt, et al.	<u>P.N.A.S. (USA)</u> , 80, pp. 3218-3222 (1982)
<i>JMY</i>	C59	Krane	<u>Henry Ford Hosp.Med.J.</u> , 31(3) 177-181 (1983)
<i>JMY</i>	C60	Krystal	<u>Expt.Hematol.</u> , 11(7), 649-660 (1983)
<i>JMY</i>	C61	Kurachi, et al.	<u>P.N.A.S. (USA)</u> , 79, pp. 6461-6464 (1982)
<i>JMY</i>	C62	Kurtz	<u>FEBS Letters</u> , 149(1), 105-108 (1982)
<i>JMY</i>	C63	Kyte, et al.	<u>J.Mol.Biol.</u> , 157, 105-132 (1982)
<i>JMY</i>	C64	Lappin, et al.	<u>Exp.Hematol.</u> , 11(7), 661-666 (1983)
<i>JMY</i>	C65	Lawn, et al.	<u>Cell</u> , 15, pp. 1157-1174 (1978)
<i>JMY</i>	C66	Lawn, et al.	<u>Cell</u> , 18 - Typographical error, should be <u>Cell</u> , 15 - See C65
<i>JMY</i>	C67	Ledeen, et al.	<u>Methods in Enzymology</u> , 83(Part D), 139-191 (1982)
<i>JMY</i>	C68	Lee-Huang	<u>Proc.Nat.Acad.Sci (USA)</u> , 81, 2708-2712 (1984)
<i>JMY</i>	C69	Lee-Huang	<u>Abstract No. 1463, Fed.Proc.</u> , 41, 520 (1982)
<i>JMY</i>	70	Lerner	<u>Scientific American</u> , 248, No. 2, 66-74 (1983)
<i>JMY</i>	71	Lerner, et al.	<u>Cell</u> , 23, 309-310 (1981)
<i>JMY</i>	72	Lerner, et al.	<u>P.N.A.S. (USA)</u> , 78, 3403-3407 (1981)

A 47878

*Considered June 2, 1986
Joanne M. Gieser*

197 214

221

Sheet 8 of 12

FORM PTO-1449

Atty. Docket No.
7183

Serial No.
675,298

Applicant: FU-KUEN LIN

Filing Date: November 30, 1984

Group Art Unit 127

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

OTHER DOCUMENTS (cont'd.)
(Including Author, Title, Date, Pertinent pages, etc.)

<i>Jmy</i>	C73	Lipschitz, et al.	<u>Blood</u> , <u>63(3)</u> , 502-509 (1983) 14
<i>Jmy</i>	C74	Maniatis, et al.	"Molecular Cloning, a Laboratory Manual", Cold Springs Harbor, N.Y. (1982)
<i>Jmy</i>	C75	McGonigle, et al.	<u>Kidney Int.</u> , <u>25(2)</u> , 437-444 (1984) 14
<i>Jmy</i>	C76	Messing	<u>Methods in Enzymology</u> , <u>101</u> , 20-78 (1983) 14
<i>Jmy</i>	C77	Methods in Yeast...	Methods in Yeast Genetics, Cold Spring Harbor Lab., Cold Spring Harbor, N.Y. p. 62 (1983) - (not enclosed)
<i>Jmy</i>	C78	Miller, et al.	<u>Brit.J.Haematol.</u> , <u>52</u> , 545-549 (1982) 14
<i>Jmy</i>	C79	Miyake, et al.	<u>J.Biol.Chem.</u> , Vol. 252, No. 15, pp. 5558-5564 (1977) 14
<i>Jmy</i>	C80	Morrison	"Bioprocessing in Space -- an Overview", pp. 557-571 in The World Biotech Report, 1984, Volume 2:USA
<i>Jmy</i>	C81	Murphy, et al.	<u>Acta.Haematologica Japonica</u> , <u>46(7)</u> , 1380-1396 (1983) 14
<i>Jmy</i>	C82	Nathan, et al.	<u>New Eng.J.Med.</u> , <u>308(9)</u> , 520-522 (1983) 14
<i>Jmy</i>	C83	Naughton, et al.	<u>Ann.Clin.Lab.Sci.</u> , <u>13(5)</u> , 432-438 (1983) 14
<i>Jmy</i>	C84	Naughton, et al.	<u>Acta.Haemat.</u> , <u>69</u> , 171-179 (1983) 14
<i>Jmy</i>	C85	Neeser, et al.	<u>Anal.Biochem.</u> , <u>142</u> , 58-67 (1984) 14
<i>Jmy</i>	C86	Nigg, et al.	<u>P.N.A.S. (USA)</u> , <u>79</u> , 5322-5326 (1982) 14

A 47879

Considered June 2, 1986
Jeanne M. Giesser

195 215

222

Sheet 9 of 12

FORM PTO-1449

Atty. Docket No.
7183

Serial No.
675,298

Applicant: FU-KUEN LIN

Filing Date: November 30, 1984

Group Art Unit 127

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

OTHER DOCUMENTS (cont'd.)

(Including Author, Title, Date, Pertinent pages, etc.)

<i>JMY</i> C87	Ohkubo, et al.	<u>P.N.A.S. (USA), 80</u> , pp. 2196-2200 (1983) ¹⁴
<i>JMY</i> C88	Okayama, et al.	<u>Mol. & Cell. Biol.</u> , <u>2</u> , 161-170 (1982) ¹⁴
<i>JMY</i> C89	Palmiter, et al.	<u>Science</u> , <u>222(4625)</u> , 809-814 (1983) ¹⁴
<i>JMY</i> C90	Pavlovic-Kentera, et al.	<u>Expt. Hematol.</u> , <u>8(Supp. 8)</u> , <u>283-291</u> (1980) ¹⁴
<i>JMY</i> C91	Pennathur-Das et al.	<u>Blood</u> , <u>63(5)</u> , 1168-71 (1984) ¹⁴
C92	Points to Consider..	"Points to Consider in the Characterization of Cell Lines Used to Product Biologics", June 1, 1984, Office of Biologics Research Review, Center for Drugs & Biologics, U.S. Food & Drug Administration (Section A, Part 2) (not enclosed).
<i>JMY</i> C93	Resegotti, et al.	<u>Panminerva Medica</u> , <u>23</u> , 243-248 (1981) ¹⁴
<i>JMY</i> C94	Reyes, et al.	<u>P.N.A.S. (USA)</u> <u>79</u> , pp. 3270-3274 (1982) ¹⁴
<i>JMY</i> C95	Ross, et al.	<u>Nature</u> , <u>294</u> , 654-656 (1981) ¹⁴
<i>JMY</i> C96	Rothmann, et al.	<u>J. Surg. Oncol.</u> , <u>20</u> , 105-108 (1982) ¹⁴
<i>JMY</i> C97	Saito, et al.	<u>Jap. J. Med.</u> , <u>23(1)</u> , 16-21 (1984) ¹⁴
<i>JMY</i> C98	Sanger, et al.	<u>P.N.A.S. (USA)</u> , <u>74</u> , 5463-5467 (1977) ¹⁴
<i>JMY</i> C99	Sasaki	<u>Biomed. Biochim. Acta.</u> , <u>42(11/12)</u> , <u>S202-206</u> (1983) ¹⁴
<i>JMY</i> C100	Schwartz, et al.	<u>Otolaryngol.</u> , <u>109</u> , 269-272 (1983) ¹⁴

A 47880

Considered June 2,

194 216

223

Sheet 10 of 12

FORM PTO-1449

Atty. Docket No.
7183

Serial No.
675,298

Applicant: FU-KUEN LIN

Filing Date: November 30, 1984 Group Art Unit 127

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

OTHER DOCUMENTS (cont'd.)

(Including Author, Title, Date, Pertinent pages, etc.)

<i>gms</i>	C101	Shahidi	<u>New.Eng.J.Med.</u> , <u>289</u> , 72-80 (1973) ₁₄
<i>gms</i>	C102	Singer-Sam, et al.	<u>P.N.A.S. (USA)</u> , <u>80</u> , pp. 802-806 (1983) ₁₄
<i>gms</i>	C103	Sue, et al.	<u>Proc.Nat.Acad.Sci. (USA)</u> , <u>80</u> , <u>3651-3655</u> (1983) ₁₄
<i>gms</i>	C104	Suggs, et al.	<u>P.N.A.S. (USA)</u> , <u>78</u> , pp. 6613- <u>6617</u> (1981) ₁₄
<i>gms</i>	C105	Sytowski, et al.	<u>Expt.Hematol.</u> , <u>8(Supp. 8)</u> , 52-63 (1980) ₁₄
<i>gms</i>	C106	Sytowski, et al.	<u>J.Immunol.Methods</u> , <u>69</u> , 181-186 (1984) ₁₄
<i>gms</i>	C107	Tambourin, et al.	<u>P.N.A.S. (USA)</u> , <u>80</u> , 6269-6273 (1983) ₁₄
<i>gms</i>	C108	Taub, et al.	<u>Anal.Biochem.</u> , <u>126</u> , 222-230 (1982) ₁₄
<i>gms</i>	C109	Testa, et al.	<u>Exp.Hematol.</u> , <u>8(Supp. 8)</u> , 144- <u>152</u> (1980) ₁₄
<i>gms</i>	C110	Tong, et al.	<u>J.Biol.Chem.</u> <u>256(24)</u> , 12666- <u>12672</u> (1981) ₁₄
<i>gms</i>	C111	Tramontano, et al.	<u>Nucleic Acids Research</u> , <u>12</u> , <u>5049-5059</u> (1984) ₁₄
<i>gms</i>	C112	Udupa, et al.	<u>J.Lab.Clin.Med.</u> , <u>103(4)</u> , 574-580 & <u>581-588</u> (1984) ₁₄
<i>gms</i>	C113	Urabe, et al.	<u>J.Exp.Med.</u> , <u>149</u> , 1314-1325 (1979) ₁₄
<i>gms</i>	C114	Urlaub, et al.	<u>Proc.Nat.Acad.Sci. (USA)</u> , <u>Vol.</u> <u>77</u> , 4216-4220 (1980) ₁₄

A 47881

Considered June 2, 1986
Jeanne M. Giesse

AS 217

224

Sheet 11 of 12

FORM PTO-1449 Atty. Docket No. 7183 Serial No. 675,298

Applicant: FU-KUEN LIN
 Filing Date: November 30, 1984 Group Art Unit 127

INFORMATION DISCLOSURE
 STATEMENT BY APPLICANT

OTHER DOCUMENTS (cont'd.)
 (Including Author, Title, Date, Pertinent pages, etc.)

<i>Jmy</i>	C115	Vedovato, et al.	<u>Acta.Haematol</u> , <u>71</u> , 211-213 (1984) 14
<i>Jmy</i>	C116	Vichinsky, et al.	<u>J.Pediatr.</u> <u>105(1)</u> , 15-21 (1984) 14
<i>Jmy</i>	C117	Wallace, et al.	<u>Nuc.Acids Res.</u> , <u>9</u> , pp. 879-894 (1981) 14
<i>Jmy</i>	C118	Wallace, et al.	<u>Nuc.Acids Res.</u> , <u>6</u> , pp. 3543-3557 (1979) 14
<i>Jmy</i>	C119	Wallace, et al.	<u>Gene</u> , <u>16</u> , 21-26 (1981) 14
<i>Jmy</i>	C120	Walter, et al.	<u>P.N.A.S. (USA)</u> , <u>78</u> , 4882-4886 (1981) 14
<i>Jmy</i>	C121	Walter, et al.	<u>P.N.A.S. (USA)</u> , <u>77</u> , 5197-5200 (1980) 14
<i>Jmy</i>	C122	Weiland, et al.	<u>Blut</u> , <u>44(3)</u> , 173-175 (1982) 14
<i>Jmy</i>	C123	Weiss, et al.	<u>P.N.A.S. (USA)</u> , <u>79</u> , 5465-5469 (1982) 14
<i>Jmy</i>	C124	Weiss, et al.	<u>Am.J.Vet.Res.</u> , <u>44(10)</u> , 1832-1835 (1983) 14
<i>Jmy</i>	C125	Wong, et al.	<u>P.N.A.S. (USA)</u> , <u>78</u> , 7412-7416 (1981) 14
<i>Jmy</i>	C126	Woo	<u>Methods in Enzymology</u> , <u>68</u> , 389-395 (1979) 14
<i>Jmy</i>	C127	World Biotech	World Biotech Report, 1984, Vol. 2:USA (See C80)
<i>Jmy</i>	C128	Yanagawa, et al.	<u>Blood</u> , <u>64(2)</u> , 357-364 (1984) 14
<i>Jmy</i>	C129	Yanagawa, et al.	<u>J.Biol.Chem.</u> , <u>259(5)</u> , 2707-2710 (1984) 14
<i>Jmy</i>	C130	Broome, et al.	<u>P.N.A.S. (USA)</u>, <u>75</u>, 2746-2749 (1978)

Considered June 2, 1986
 Joanne M. Gieser
A 47882
 225
 218

Sheet 12 of 12

FORM PTO-1449

Atty. Docket No.
7183

Serial No.
675,298

Applicant: FU-KUEN LIN

Filing Date: November 30, 1984 Group Art Unit 127

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

OTHER DOCUMENTS (cont'd.)
(Including Author, Title, Date, Pertinent pages, etc.)

<i>Jmy</i> C131	Dunn, et al.	<u>Chemical Abstracts</u> , <u>91</u> , 190417r (1979)
<i>Jmy</i> C132	Grantham, et al.	<u>Nuc. Acids. Res.</u> , <u>9</u> , r43-r74 (1981) ₁₄
<i>Jmy</i> C133	Bennetzen, et al.	<u>J. Biol. Chem.</u> , <u>257</u> , 3026-3031 (1982) ₁₄
<i>Jmy</i> C134	Hamer, et al.	<u>Nature</u> , <u>281</u> , 35-40 (1979) ₁₄

*Considered June 2, 1986
Joanne M. Giesser*

A 47883

226

199 219